Abstract
Objective:
To characterize and evaluate hematopoietic colony-stimulating factor (CSF) use, including cost implications, in US academic health centers.
Design:
An observational study of patients who received granulocyte colony-stimulating factor (G-CSF) or granulocytemacrophage colony-stimulating factor (GM-CSF) from September 1 to October 15, 1993.
Setting:
Thirty academic health centers in the US.
Participants:
Five hundred sixty-five patients were evaluated.
Main Outcome Measures:
The appropriateness of CSF use was assessed, based on consensus-derived indication guidelines and the Food and Drug Administration-approved product labeling. Indication, type of CSF, and dosage were considered in determining the appropriateness of CSF therapy.
Results:
Based on indication evaluation criteria, 71% of CSF use was appropriate, 7% was inappropriate, and 22% was unproven, although the majority of unproven use was deemed promising by the expert panel. Based on dosage evaluation criteria, 51% of CSF use was appropriate, 27% was inappropriate, and 22% was for promising and other unproven indications. More than 90% of the patients studied received G-CSF. Approximately 3.4% of patients who received G-CSF had an adverse event, compared with 22% of those who received GM-CSF. Approximately $791 000 was spent on CSF therapy in the 565 patients: $401 000 (51%) on appropriate indications and doses, $160 000 (20%) on inappropriate doses for appropriate indications, $124 000 (16%) on promising indications, and $106 000 (13%) on unproven or inappropriate indications.
Conclusions:
Substantial costs are incurred currently for CSF therapy without adequate literature support. Further studies are warranted to justify promising but unproven uses of CSFs, as well as to clarify proper dosing, monitoring, and relative safety of CSFs.
Get full access to this article
View all access options for this article.